Education
About Us
Working with TipRanks
Follow Us
Elicera Therapeutics AB (DE:8E8)
:8E8
8E8 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.08 - €0.65
Previous CloseN/A
Volume0.00
Average Volume (3M)333.00
Market Cap
€24.94M
Enterprise Value€74.56M
Total Cash (Recent Filing)€26.40M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.65
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding48,535,545
10 Day Avg. Volume0
30 Day Avg. Volume333
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)121.48
Price to Sales (P/S)0.00
P/FCF Ratio-311.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
8E8 FAQ
What was Elicera Therapeutics AB’s price range in the past 12 months?
Elicera Therapeutics AB lowest stock price was €0.08 and its highest was €0.65 in the past 12 months.
What is Elicera Therapeutics AB’s market cap?
Elicera Therapeutics AB’s market cap is €24.94M.
When is Elicera Therapeutics AB’s upcoming earnings report date?
Elicera Therapeutics AB’s upcoming earnings report date is Aug 27, 2025 which is in 68 days.
How were Elicera Therapeutics AB’s earnings last quarter?
Elicera Therapeutics AB released its earnings results on Apr 29, 2025. The company reported -€0.02 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.02.
Is Elicera Therapeutics AB overvalued?
According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued.
Does Elicera Therapeutics AB pay dividends?
Elicera Therapeutics AB does not currently pay dividends.
What is Elicera Therapeutics AB’s EPS estimate?
Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elicera Therapeutics AB have?
Elicera Therapeutics AB has 48,535,545 shares outstanding.
What happened to Elicera Therapeutics AB’s price movement after its last earnings report?
Elicera Therapeutics AB reported an EPS of -€0.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of Elicera Therapeutics AB?
Currently, no hedge funds are holding shares in DE:8E8
Company Description
Elicera Therapeutics AB
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.
Technical Analysis
Medivir AB
―
Alligator Bioscience AB
―
Biosergen AB
―
Active Biotech AB
―
CombiGene AB
―